Here we discuss the advantages and pitfalls of HIPEC in advanced ovarian cancer, as well as current data and ongoing prospective trials.
Oliver Zivanovic, MD, PhD
Advertisement
Articles by Oliver Zivanovic, MD, PhD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CancerNetwork
1
Capivasertib Combo Earns FDA Approval in PTEN-Deficient Metastatic HSPC
2
FDA Approves Adjuvant Belzutifan/Pembrolizumab in Clear Cell RCC Post Nephrectomy
3
Anbenitamab Regimen Meets Phase 3 End Points in HER2+ Breast Cancer
4
Tisa-Cel Yields Enduring Remissions in Younger High-Risk B-ALL Population
5